Spiramycin
ApprovedSmall molecule
Spiramycin is one of 12 small molecule programs targeting Congenital Toxoplasmosis. It is currently in Approved.
3
Indications
3
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Cryptosporidiosis
#DrugCompanyPhaseTrials
1Alinia
RRomark Laboratories L.C.
Phase 3
Lamprene
NovartisPhase 2
Spiramycin
RRhone-Poulenc Rorer
Approved
IL-12
PfizerPhase 2
Paromomycin Sulfate
PPATH
Phase 2
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Echinacea Extract
AAl-Azhar University
Phase 2
Interleukin-12
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Diclazuril
Johnson & JohnsonPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cryptosporidiosis1 trial
Congenital Toxoplasmosis1 trial
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00004317·600 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Spiramycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- RRhone-Poulenc Rorer